The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation
Open accessAbstract
INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5) are currently the first line treatment for erectile dysfunction (ED). However, previous research shows that PDE5 treatments have high discontinuation rates. Understanding the reasons for discontinuing PDE5 will be necessary to optimize the response to treatment. AIM: The main goals were: (i) to analyze discontinuation rate of PDE5; (ii) to identify the discontinuation predictors; and (iii) to study the reasons for discontinuation using a qualitative methodology. MAIN OUTCOME MEASURES: The PDE5 discontinuation rates, predictors, and reasons for discontinuation treatment. METHODS: A total of 327 men with clinical diagnosis for ED who had been treated with PDE5 were successfully interviewed by telephone, after giving their informed consent by snail mail. Telephone interviews, concerning their ongoing treatment, were carried out using a standardized questionnaire form with quantitative and qualitative items. Participation rate was 71.8%. RESULTS: Of the total sample, 160 men (48.9%) had discontinued PDE5 treatment. The discontinuation rate was higher among men with diabetes (73%) and in iatrogenic group (65%), and lower in venogenic etiology (38.7%). We differentiated three groups of men who discontinued treatment (i) during the first 3 months (55.1%); (ii) between 4 and 12 months (26.9%); and (iii) after a period of 12 months (18%). Qualitative analyses revealed diverse reasons for discontinuation: non-effectiveness of PDE5 (36.8%), psychological factors (e.g., anxiety, negative emotions, fears, concerns, dysfunctional beliefs) (17.5%), erection recovery (14.4%), and concerns about the cardiovascular safety of PDE5 (8.7%) were the most common. Older men and men whose partners were involved in the treatment, were less likely to discontinue treatment. CONCLUSION: Half the subjects discontinued medication. Mostly, there was a combination of factors that led to discontinuation: non-effectiveness and psychosocial factors appear to be the main reasons. Addressing those factors will allow following up with appropriate focus on relevant topics in order to improve compliance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and discontinuation rates are exceedingly high (50–61%) irrespective of treatment effectiveness.21, 22, 23, 24, 25, 26”
From Preliminary Development of a Mindfulness-Based Group Therapy to Expand Couples’ Sexual Intimacy after Prostate Cancer: A Mixed Methods Approach (2021) · cites this paper as [25]
In the citing paper
“Research has shown that more than 50% of the couples do not adhere to medical aids for erectile function after the first year of treatment.99,100,102”
From A Psychosocial Approach to Erectile Dysfunction: Position Statements from the European Society of Sexual Medicine (ESSM) (2021) · cites this paper as [99]
In the citing paper
“Although medical treatments have been shown to be physiologically effective, long-term adherence to medical treatment is poor and erectile function recovery is not always achieved, often depending on how well men are instructed about (correct) use of the medical aids.99, 100, 101”
From A Psychosocial Approach to Erectile Dysfunction: Position Statements from the European Society of Sexual Medicine (ESSM) (2021) · cites this paper as [99]
In the citing paper
“In addition, therapy should identify and treat underlying relational dynamics because relationship conflicts are an important reason for lack of compliance or drop-out.59,99”
From A Psychosocial Approach to Erectile Dysfunction: Position Statements from the European Society of Sexual Medicine (ESSM) (2021) · cites this paper as [99]
Citations
Cites
Researching Lived Experience: Human Science for an Action Sensitive Pedagogy
van Manen, M. (1990) · Medical Entomology and Zoology · Cited by 11,308
Handbook of Qualitative Research
Londoño Fernández, J. L. (1994) · Journal of Environmental Psychology · doi:10.1016/s0272-4944(05)80230-0 · Cited by 5,754
Constructivist, interpretivist approaches to human inquiry.
Schwandt, T. A. (1994) · Cited by 2,465
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’
Braun, M., Wassmer, G., Klotz, T., Reifenrath, B., Mathers, M. J., & Engelmann, U. H. (2000) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900622 · Cited by 996
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199809000-00020 · Cited by 740
Oral Sildenafil in the Treatment of Erectile Dysfunction
(1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390121 · Cited by 623
Pharmacotherapy for Erectile Dysfunction
Ian Eardley, C., Donatucci, C. F., Corbin, J. D., El-Meliegy, A., Konstantinos Hatzimouratidis, A., McVary, K. T., Munarriz, R. M., & Lee, S. W. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01627.x · Cited by 254
When an erection alone is not enough: biopsychosocial obstacles to lovemaking
Althof, S. E. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900799 · Cited by 184
The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update
Carson, C. C., Burnett, A. L. “., Levine, L. A., & Nehra, A. X. (2002) · Urology · doi:10.1016/s0090-4295(02)01687-4 · Cited by 171
“Viagra stories”: challenging ‘erectile dysfunction’
Potts, A., Grace, V. M., Gavey, N., & Vares, T. (2004) · Social Science & Medicine · doi:10.1016/j.socscimed.2003.06.001 · Cited by 131
Raina, R., Lakin, M. M., Agarwal, A. K., Sharma, R. K., Goyal, K. K., D, D. K. M. M., Klein, E. A., & Zippe, C. D. (2003) · Urology · doi:10.1016/s0090-4295(03)00157-2 · Cited by 103
Salonia, A., Andrea Gallina, A., Zanni, G. E., Briganti, A., Dehò, F., Saccà, A., Suardi, N. R., Barbieri, L., Guazzoni, G. F., Rigatti, P., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.08.016 · Cited by 101
Hatzichristou, D. G., Moysidis, K., Apostolidis, A., Bekos, A., Tzortzis, V., Konstantinos Hatzimouratidis, A., & Ioannidis, E. (2005) · European Urology · doi:10.1016/j.eururo.2004.12.005 · Cited by 99
Corona, G., Mondaini, N., Ungar, A., Razzoli, E., Rossi, A., & Fusco, F. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02473.x · Cited by 96
Compliance of sildenafil treatment for erectile dysfunction and factors affecting it
Jiann, B.-P., Yu, C.-C., Su, C.-C., & Tsai, J.-Y. (2005) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901379 · Cited by 88
Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)?
Klotz, T., Mathers, M., Klotz, R., & Sommer, F. (2005) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901252 · Cited by 81
Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users
Souverein, P. C., Egberts, T. C. G., MEULEMAN, E. J. H., Urquhart, J., & Leufkens, H. G. M. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900883 · Cited by 79
Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function.
HwancheolSon, KwanjinPark, SooWoongKim, & Jae-SeungPaick (2004) · PubMed · Cited by 72
Ljunggren, C., Hedelin, H. H., Salomonsson, K., & Ströberg, P. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00688.x · Cited by 51
Challenges in Oral Therapy for Erectile Dysfunction
Seftel, A. D. (2002) · Journal of Andrology · doi:10.1002/j.1939-4640.2002.tb02323.x · Cited by 51
Clinical Efficacy of sildenafil Citrate and Predictors of Long-term Response
Gonzalgo, M. L., Brotzman, M. J., Trock, B. J., Geringer, A. M., Burnett, A. L. “., & Jarow, J. P. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000071478.69480.fd · Cited by 42
Is Sex Only for the Healthy and Wealthy?
Ströberg, P., Hedelin, H. H., & Bergström, A. (2006) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2006.00233.x · Cited by 30
Sato, Y., Tanda, H., Kato, S., Onishi, S., Nitta, T., & Koroku, M. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01608.x · Cited by 25
Failure of PDE5 Inhibitor Use: A Case of Nonresponder? (CME)
Chung, E. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01772.x · Cited by 4
Salvaging the oral treatment failure patient
Pescatori, E. S., Drei, B., Morgia, G., & Farina, F. P. (2006) · Current Sexual Health Reports · doi:10.1007/s11930-006-0022-6 · Cited by 1
Research works printed but not linked: 2
- Basar, 2003, Causes of sildenafil citrate treatment discontinuation in erectile dysfunction patients (poster section P-026), Int J Impot Res, 15, S51
- Casabe, 2001, Drop out reasons in responders to sildenafil (moderated poster 9), Int J Impot Res, 13, S5
Cited by
Sorted by citations
Konstantinos Hatzimouratidis, A., Salonia, A., Adaikan, G. P., Buvat, J., Carrier, S., El-Meliegy, A., McCullough, A., Torres, L. O., & Khera, M. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.01.016 · Cited by 252
Sexual dysfunction and infertility as late effects of cancer treatment
Schover, L. R., van der Kaaij, M. A. E., van Dorst, E. B. L., Creutzberg, C. L., Huyghe, É., & Kiserud, C. E. (2014) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2014.03.004 · Cited by 234
Bruzziches, R., Francomano, D., Gareri, P., Lenzi, A., & Aversa, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.799665 · Cited by 104
Salonia, A., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., McCullough, A., Morgentaler, A., Torres, L. O., & Khera, M. (2017) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.11.324 · Cited by 102
Corona, G., Rastrelli, G., Burri, A. V., Serra, E., Gianfrilli, D., Mannucci, E., Jannini, E. A., & Maggi, M. (2016) · Andrology · doi:10.1111/andr.12255 · Cited by 97
Metadata
- Authors
- Carvalheira, A. A., Pereira, N. M., Maroco, J., & Forjaz, V.
- Affiliations
- Research Unit of Psychology and Health, University Institute of Applied Psychology , Lisbon , Portugal
- iSex—Association for the Advanced Study of Human Sexuality, ULHT , Lisbon , Portugal
- Corresponding author
- Carvalheira, Ana A.
- Venue
- The Journal of Sexual Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-01
- Volume
- 9
- Issue
- 9
- Pages
- 2361-2369
- ISSN
- 1743-6095 (ISSN-L)
- 1743-6109
- OpenAlex
- W1514818611
- Cited by
- 132
- References
- 26
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 8 · 2022: 9 · 2021: 8 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 12 · 2016: 12 · 2015: 15 · 2014: 13 · 2013: 4 · 2012: 2
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Journal of Sexual Medicine (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Health Sciences › Medicine › Urology › Urological Disorders and Treatments
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Keywords
- erectile dysfunction, phosphodiesterase-5 inhibitors, treatment discontinuation, predictors of discontinuation, reasons for discontinuation, treatment effectiveness, psychosocial factors, anxiety, diabetes mellitus, partner involvement, medication adherence
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Diabetes Mellitus, Humans, Iatrogenic Disease, Erectile Dysfunction, Male, Middle Aged, Patient Dropouts, Sexual Partners, Logistic Models, Impotence, Vasculogenic, Medication Adherence, Phosphodiesterase 5 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
